Brief by Shorts91 Newsdesk / 04:12am on 26 Sep 2025,Friday India Global
From October 1, 2025, the US will levy 100 percent tariffs on branded and patented pharmaceutical imports—unless the company is actively building a drug manufacturing plant in the United States. The exemption applies even to firms that have “broken ground” or are under construction. The policy also includes high duties on furniture and heavy trucks, sparking concern over its impact on global supply chains. Analysts warn India’s pharma exports could face significant disruption unless firms pivot U.S. investments quickly.
